Prof. Hank F. Kung (孔繁渊教授)
lDepartments of Radiology and Pharmacology University of Pennsylvania
lBeijing Institute for BrainDiseases Beijing CapitalMedical University
Research areas:
1.Discovery and development of new neuroimaging agents ofPET/SPECT: neurodegenerative diseases, cerebral amyloid angiopathy(CAA), epilepsy, depressive disorders, autismdisorder andschizophrenia.2.Development of new tumor imagingagents: glutaminemetabolism in cancer patients andaromatase activity in different regions of thebrain and tumor tissues.
²The originalinventor of importantPET/SPECT imaging agents in clinical use:
Øβ-amyloidplaquesPET imagingagentsinthe brain for assisting the diagnosis of Alzheimer’s disease (AD): [18F]AV-45 (florbetapir,Amyvid:FDA first approved in2012 ) and [18F]AV1 (florbetaben, Neurqceq: approved by the FDA in 2014).
ØVMAT2imagingagent - [18F]AV133for PD(phase III in US)
ØC-11and F-18 Glutamine metabolism imaging agent forTumor (phase I-II in US)
ØDATimaging agent - 99mTc-Trodat-1forSPECT imaging in Parkinson disease
ØD2/D3imaging agent *I-IBZM and5HTTimaging agent *I-ADAM et al.²received more than 40 patents.
²Receive dawards:
Ø2014 David and Jane ChuLectureship, University of Buffalo
Ø2013 Kuhl-LassenAwardfor Research in Brain Imaging, Society of Nuclear Medicine(SNMMI)
Ø2012 Distinguished Investigator,Academy of Radiology Research
Ø2004 PaulC. AebersoldAward for outstanding achievement in basic science applied to nuclear medicine,Society of Nuclear Medicine
Ø1997 Springer Award for the BestPaper in Basic Science, European Society of Nuclear Medicine
Ø1988 Jacob JavitsAward for Neuroscience, NIH
近5年代表性论文:
lScience,2013, 342:429-30;
lBioconjugChem.2016, 27:1314;
lJ.Med. Chem. 2016;59:9370-80;
lJ.Nucl. Med. 2017;58:533-7;
lCancer Res. 2017;77:1476-84.